Go or no go? Vaccines and neurology up for discussion
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer.
Asco-GU – Talzenna remains a wait-and-see story in prostate cancer
Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.
Sanofi and Regeneron face a high-risk test for Dupixent
A pivotal readout approaches in COPD, where other biologicals have fallen short.
Asco-GU – Bicycle tries to put distance between itself and Seagen
However, results with BT8009, one of several datasets being presented this week at the Asco-GU conference, fail to convince many investors.
